Vaxart Files Proxy Materials, No Fee Required
Ticker: VXRT · Form: DEFA14A · Filed: Apr 28, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | DEFA14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, proxy-statement, biotech
Related Tickers: VXRT
TL;DR
Vaxart (VXRT) filed proxy docs, no fee. Standard shareholder update.
AI Summary
Vaxart, Inc. filed a Definitive Additional Materials (DEFA14A) on April 28, 2025. This filing relates to the company's proxy statement and indicates no fee was required for this filing. Vaxart, Inc. is a biotechnology company focused on biological products.
Why It Matters
This filing is a routine regulatory submission for Vaxart, Inc., providing updated information to shareholders regarding corporate matters and proxy voting.
Risk Assessment
Risk Level: low — This filing is a standard DEFA14A, which is a routine regulatory disclosure and does not inherently present new risks.
Key Numbers
- 001-35285 — SEC File Number (Identifies Vaxart's SEC filing series.)
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- 0001437749-25-013356 (filing_id) — Accession Number
- 20250428 (date) — Filing Date
- 170 Harbor Way, Suite 300 (address) — Business Address
- South San Francisco, CA 94080 (address) — Business Address
- Aviragen Therapeutics, Inc. (company) — Former Company Name
- Biota Pharmaceuticals, Inc. (company) — Former Company Name
- NABI BIOPHARMACEUTICALS (company) — Former Company Name
FAQ
What type of filing is this DEFA14A for Vaxart, Inc.?
This filing is classified as Definitive Additional Materials (DEFA14A).
When was this DEFA14A filing submitted to the SEC?
The filing was submitted on April 28, 2025.
Does Vaxart, Inc. have any former company names listed in this filing?
Yes, Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.
What is Vaxart, Inc.'s primary business classification?
Vaxart, Inc. is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Was there a filing fee associated with this DEFA14A submission?
No, the filing indicates that no fee was required for this submission.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 28, 2025 regarding Vaxart, Inc. (VXRT).